A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
about
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolismDuration of treatment with vitamin K antagonists in symptomatic venous thromboembolismAntithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesXimelagatran: direct thrombin inhibitorThe role of dyslipidemia and statins in venous thromboembolismDetection and quantification of lupus anticoagulants in plasma from heparin treated patients, using addition of polybreneManagement of Venous Thromboembolisms: Part I. The Consensus for Deep Vein ThrombosisEdoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous ThromboembolismRecurrent venous thromboembolism: what is the risk and how to prevent itMajor bleeding during secondary prevention of venous thromboembolism in patients who have completed anticoagulation: a systematic review and meta-analysisPredicting the risk of venous thromboembolism recurrenceThe epidemiology of venous thromboembolismDiagnosis and Treatment of Lower Extremity Deep Vein Thrombosis: Korean Practice GuidelinesLimited evidence on persistence with anticoagulants, and its effect on the risk of recurrence of venous thromboembolism: a systematic review of observational studiesGuidance for the treatment of deep vein thrombosis and pulmonary embolismDuration of anticoagulation for venous thromboembolic eventsExtended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-AnalysisAntiaggregant and anticoagulant therapy in systemic lupus erythematosus and Hughes' syndromeUnresolved issues in anticoagulant therapyThe impact of vitamin K-dependent factor depletion by warfarin on platelet-rich thrombosis after deep arterial injuryAmerican College of Medical Genetics consensus statement on factor V Leiden mutation testingGuidelines for warfarin therapy following a thromboembolic eventCerebral Sinus Thrombosis.Review of venous thromboembolism and race: the generalizability of treatment guidelines for high-risk populations.Progression of antiphospholipid antibody syndrome to catastrophic antiphospholipid antibody syndrome acutely with cessation of antithrombotic therapy.Diagnosis and treatment of deep vein thrombosis.Residual vein obstruction as a predictor for recurrent thromboembolic events after a first unprovoked episode: data from the REVERSE cohort study.The epidemiology of venous thromboembolism in the community.Warfarin therapy: a review of the literature since the Fifth American College of Chest Physicians' Consensus Conference on Antithrombotic Therapy.Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trialsComparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism: a meta-analysis of randomized, controlled trials.Criteria for evaluating evidence that laboratory abnormalities are associated with the development of venous thromboembolism.Long-term outcomes after deep vein thrombosis: postphlebitic syndrome and quality of lifeDuration of treatment with vitamin K antagonists in symptomatic venous thromboembolism.XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis.Radiofrequency radiation exposure and other environmental concernsLong-term survival after venous thromboembolism: a retrospective selected cohort study among young women.Anticoagulation for venous thromboembolism. What are the current options?Evaluation of the hypercoagulable state. Whom to screen, how to test and treat.Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009)
P2860
Q24194466-1F06D42E-C18C-4498-9FDB-D3258E76E1F2Q24244786-25B5E0AD-1C20-486F-AF42-78B17EA3F9F5Q24633053-E02CBAA8-33B6-4695-8AB4-74CB2382ED36Q24681333-EFE9302B-36CA-4BF2-B15C-6F54CEE11E52Q24793360-8A8A2077-C50B-4A8F-8F94-C7FE3F670644Q25257768-854EE94F-65F6-4719-8862-6B0AB2D82460Q26749273-DB2EB09D-33A8-47CC-915C-1A6F3E9DC2C7Q26764998-D1C5B491-56C6-4E22-9559-374FDD782096Q26826847-5AB61512-8613-4BEE-8904-AF53C0E24A10Q26828750-A76CD686-1BBD-46FE-8300-F2BAC360BE8AQ26865059-FE012027-0686-4C24-939A-34D212CA64E9Q28067893-44EA8192-62C1-45CD-BD3C-C658B540F9DCQ28072833-C95527F0-94F7-4D7A-A188-078A3EB90F47Q28078824-A9D70E2E-B97E-470E-80A2-5AE750760FD8Q28078989-E823342C-605D-4661-AF3B-1F720D64D4FFQ28081375-FD58C411-6ADF-4690-8DF8-44AFABB23630Q28081717-AF808AF2-1610-42A0-ABF1-DB42F6CC1C65Q28182136-F044BA1E-D76E-4CCC-9C01-455D847CFA4DQ28196778-4887E808-6E4B-4E9C-8A83-8274FA9F41FCQ28214027-C9276BC2-EBA1-40F3-AE4A-05B72E0E0E0BQ28361651-C2B56F16-9D59-4969-A9E5-2DCA2609624DQ28365437-46DF4328-7359-49AE-B2D0-116ADCB6915CQ30249288-F1CF91A9-3008-41CB-8373-6B151AEDFCB6Q30251792-554B8004-A3B5-4D25-A55D-EDAE7EA04402Q33401365-2D2826FD-779D-4559-8C0C-7A5891825B05Q33728135-AE4E35C5-FFF4-4327-8025-7A33B3D7DD28Q33821311-2527534F-C5CE-4BD3-803C-0C68ADB5BE53Q33865646-D5578E99-9049-46E2-A82D-94650436F083Q33868340-0C4A523D-CD6C-4CFF-8F5A-AF39D7552F9AQ33910755-B546AD55-1E98-434A-9A61-7D6A9A1D9E54Q33917883-BBC75B91-975C-40DD-8E02-351F21803D85Q33954905-4F54CBC8-DE58-4136-AA7B-FDDBBACB07A1Q33962232-F54550A0-1514-463F-AF9A-C29D5E46F6C4Q33978357-A48FDF9C-E83E-452B-9001-A573144FB44EQ33997674-7D30FB3D-8AE6-4ACF-928F-1E140BF23DEBQ34031468-5BCE3E78-4484-40BD-872D-C2EA96B4F0DDQ34032280-13887915-72A3-4949-B26C-6ACCC440DB7AQ34054473-55217F38-7471-4F2C-9899-044747E5AF0EQ34054479-BD63B9DE-4A33-46DD-A6D6-C5AB7982585BQ34167655-08F56877-0B09-43CD-A481-7DB004ADB67C
P2860
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
A comparison of three months o ...... pathic venous thromboembolism.
@en
A comparison of three months o ...... pathic venous thromboembolism.
@nl
type
label
A comparison of three months o ...... pathic venous thromboembolism.
@en
A comparison of three months o ...... pathic venous thromboembolism.
@nl
prefLabel
A comparison of three months o ...... pathic venous thromboembolism.
@en
A comparison of three months o ...... pathic venous thromboembolism.
@nl
P2093
P1476
A comparison of three months o ...... pathic venous thromboembolism.
@en
P2093
Anderson DR
Ginsberg JS
MacKinnon B
P304
P356
10.1056/NEJM199903253401201
P407
P577
1999-03-01T00:00:00Z